BioNTech SE (BNTX) Long-Term Deferred Tax (2018 - 2025)
BioNTech SE (BNTX) posted Long-Term Deferred Tax of $15.7 million for Q4 2025, down 24.06% sequentially from $20.7 million in Q3 2025, and down 82.0% YoY from $87.3 million in Q4 2024.
BioNTech SE (BNTX) Long-Term Deferred Tax (2018 - 2025) Analysis & Trends
BioNTech SE has reported Long-Term Deferred Tax for 8 years, with the latest figure at $15.7 million in Q4 2025.
- Quarterly Long-Term Deferred Tax fell 82.0% year-over-year to $15.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.7 million (down 82.0% YoY) and the FY2025 annual result came in at $15.3 million, down 82.53% from the prior year.
- Long-Term Deferred Tax slipped to $15.7 million in Q4 2025 per BNTX's latest filing, from $20.7 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $346.5 million in Q3 2022 and troughed at $15.7 million in Q4 2025.
- A 5-year average of $139.5 million and a median of $98.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2023 and 2025: Long-Term Deferred Tax soared 223.29% in 2023, then plunged 82.0% in 2025.
- Over 5 years, Long-Term Deferred Tax stood at $170.9 million in 2021, then surged by 37.05% to $234.2 million in 2022, then slumped by 62.66% to $87.5 million in 2023, then declined by 0.19% to $87.3 million in 2024, then slumped by 82.0% to $15.7 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $15.7 million, $20.7 million, and $88.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.71 Mn |
| Sep 30, 2025 | 20.69 Mn |
| Jun 30, 2025 | 88.07 Mn |
| Mar 31, 2025 | 89.94 Mn |
| Dec 31, 2024 | 87.30 Mn |
| Sep 30, 2024 | 99.61 Mn |
| Jun 30, 2024 | 110.17 Mn |
| Mar 31, 2024 | 98.86 Mn |
| Dec 31, 2023 | 87.47 Mn |
| Sep 30, 2023 | 226.54 Mn |
| Jun 30, 2023 | 260.80 Mn |
| Mar 31, 2023 | 263.51 Mn |
| Dec 31, 2022 | 234.25 Mn |
| Sep 30, 2022 | 346.54 Mn |
| Jun 30, 2022 | 80.67 Mn |
| Mar 31, 2022 | 90.57 Mn |
| Mar 31, 2021 | 170.92 Mn |
| Dec 31, 2020 | 192.20 Mn |
| Dec 31, 2019 | 6.49 Mn |
| Sep 30, 2019 | 8.84 Mn |